Non-Small Cell Lung Cancer

Latest News

Krazati packaging | Image credit: Mirati Therapeutics
Updated KRYSTAL-7 Data Show PFS Beyond 27 Months for Adagrasib Plus Pembro in First-Line Treatment of KRAS-Mutated NSCLC

March 28th 2025

Phase 2 results reported at the European Lung Cancer Conference show a favorable signal for overall survival for the first-line treatment of KRAS-mutated non–small cell lung cancer (NSCLC). A phase 3 trial is enrolling now.

Ioana Bonta, MD
NSCLC Advancements Offer Hope, but Disparities Persist

February 20th 2025

Ryan Nguyen, DO
AI in Oncology: Opportunities and Challenges for NSCLC

January 1st 2025

WCLC Highlights Thumbnail
ICYMI: Highlights From WCLC 2024

December 27th 2024

Ryan Nguyen, MD
Precision Oncology in NSCLC: Overcoming Patient Selection Barriers

December 23rd 2024

More News

Global currency | Image Credit: Panuwat-stock.adobe.com
May 30th 2024

Durvalumab's High Costs Hinder Global Uptake for Stage III NSCLC Maintenance Therapy

Maggie L. Shaw
This international study, incorporating data from the US, Brazil, Singapore, and Spain, shows that durvalumab as maintenance therapy for use against non–small cell lung cancer remains a cost-prohibitive treatment option.
Lung cancer awareness | Image Credit: WindyNight-stock.adobe.com
May 24th 2024

Body Composition Changes Linked to Poor NSCLC Outcomes

Maggie L. Shaw
For this analysis of how body composition might affect the impact of immunotherapy used to treat non–small cell lung cancer (NSCLC), investigators from Dana-Farber Brigham Cancer Center compared patient outcomes based on baseline body composition measurements or first follow-up scan.
EGFR mutation test | Image Credit: Saiful52-stock.adobe.com
May 21st 2024

ASCENT Trial: Optimizing TKI Therapy for EGFR-Mutant NSCLC Challenges

Maggie L. Shaw
Investigators continue to seek more information on how to optimally integrate treatment with tyrosine kinase inhibitors (TKIs) into an established concurrent chemoradiotherapy regimen.
KRAS mutation | Image Credit:InnovationCreation-stock.adobe.com
May 18th 2024

Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation

Maggie L. Shaw
Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Clinical research graphic | Image Credit: Karan - stock.adobe.com
May 8th 2024

Integrating RECIST and Clinician Approaches Boosts NSCLC Research

Maggie L. Shaw
Outcomes among patients with stage IV non–small cell lung cancer as evaluated within clinical trials via Response Evaluation Criteria in Solid Tumors (RECIST) and clinician response criteria in observational studies were compared for their concordance and reliability.
Magnified lung cancer | Image credit: Laszlo - stock.adobe.com
May 3rd 2024

Positive 5-Year Results for Gefitinib Combo in EGFR-Variant Lung Cancer

Luke Halpern
Consistent with previous observations, overall survival and progression-free survival remained strong at the follow-up point.
Oncologist examining lung cancer results | Image Credit: vladislav - stock.adobe.com
April 27th 2024

Durvalumab Confirmed Beneficial After NSCLC Chemoradiotherapy

Maggie L. Shaw
This analysis evaluated patient-related outcomes between those who did and did not receive consolidation durvalumab after chemoradiotherapy for unresectable stage III non–small cell lung cancer.
Lung cancer concept | Image Credit: ivelinradkov - stock.adoe.com
April 24th 2024

Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC

Gayle Turim Dickstein
For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Lung cancer concept | Image Credit: DraganaGordic - stock.adobe.com
April 20th 2024

Alectinib Significantly Improves Disease-Free Survival in ALK-Positive NSCLC

Maggie L. Shaw
Seeking more data on adjuvant alectinib in patients who have resectable ALK-positive non–small cell lung cancer (NSCLC), investigators compared outcomes vs chemotherapy.
Shackled with bills | Image Credit: petrovk - stock.adobe.com
April 17th 2024

Financial Strain, Quality of Life Top Unmet Needs in Lung Cancer Survivors

Maggie L. Shaw
The data for this analysis on survivors of lung cancer came from Johns Hopkins Sidney Kimmel Comprehensive Cancer Center thoracic oncology clinics.
Lung cancer in black marker | Image Credit: MPStudio - stock.adobe.com
April 11th 2024

Expert Analysis Reveals Critical Insights for Optimizing Care in LA-NSCLC

Maggie L. Shaw
Authors conducted a systematic literature review to gather evidence on the appropriateness of recommended treatments for locally advanced non–small cell lung cancer (LA-NSCLC) from the American Radium Society Appropriate Use Criteria Thoracic Committee.
Intravenous drip in the pole against the bright light | Image Credit: sudok1 - stock.adobe.com
April 9th 2024

Neoadjuvant Chemoimmunotherapy Shows Superiority in Non–Small Cell Lung Cancer Treatment

Giuliana Grossi
The study compared the adverse events and surgical, pathological, and efficacy outcomes associated with neoadjuvant chemoimmunotherapy vs chemotherapy, particularly focusing on patients with PD-L1 levels less than 1%.
Medical doctor drawing lung cancer on the virtual screen | Image Credit: WrightStudio - stock.adobe.com
April 2nd 2024

Navigating Complexity: Understanding Variations in Lung Cancer Screening Decision-Making

Maggie L. Shaw
This analysis found the complex decision-making process of lung cancer screening among eligible individuals is infused with 3 principal themes that may influence how primary care physicians approach patients with comorbidities.
Wearable tech activity tracker | Image Credit: Orxan - stock.adobe.com
March 28th 2024

Wearable Activity Tracker Data Enhance Patient Assessment in Lung Cancer

Maggie L. Shaw
This analysis included 119 patients with advanced lung cancer, who were evaluated on 3 facets of physical activity over 14 days of using the amuelink wearable device from Sony: metabolic equivalent tasks, distance walked, and steps taken.
Gene expression profiling on blue backgound | Image Credit: dariaren - stock.adobe.com
March 23rd 2024

Experts Sound the Alarm on Lack of Comprehensive Genomic Profiling in NSCLC

Maggie L. Shaw
Investigators examined the downstream effect of single-gene testing for guideline-recommended biomarkers on comprehensive genomic profiling in non–small cell lung cancer (NSCLC).
A lung specialist | Image Credit: mi_viri - srock.adobe.com
March 21st 2024

Low Screening Rates for Lung Cancer Highlight Public Health Priority

Maggie L. Shaw
Overall rates for lung cancer screening remain low, despite the US Preventive Services Task Force revising its annual screening recommendation in 2021 by lowering the age of initial screening for current or former smokers and their pack-year history.
Doctor lung cancer tablet | Image Credit: © steph photographies - stock.adobe.com
March 15th 2024

ctDNA Holds Potential to Guide Management of EGFR-Mutated NSCLC

Christina Mattina
A review explores the evidence supporting the use of circulating tumor DNA (ctDNA) liquid biopsies to help direct the evaluation and management of EGFR-mutated non–small cell lung cancer (NSCLC), including for assessing resistance to certain treatment options.
Joshua K. Sabari, MD, NYU Langone Perlmutter Cancer Center
March 14th 2024

Dr Joshua Sabari Looks to the Future of Targeted Treatment for NSCLC

Maggie L. Shaw
March 1 saw the FDA grant full approval to amivantamab plus chemotherapy for first-line use in patients who have non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, converting the May 2021 accelerated approval for this treatment in the second line.
Women undergoing radiation for cancer | Image Credit: My Ocean studio - stock.adobe.com
March 12th 2024

SABR Likely Safe, Effective for Patients Who Have NSCLC, ILD

Maggie L. Shaw
In this study, the 42-patient population was enrolled from 5 sites in Canada and 1 site in Scotland, and data were gathered from March 7, 2019, to January 12, 2022; all had interstitial lung disease (ILD) and early-stage non–small cell lung cancer (NSCLC).
Joshua K. Sabari, MD< NYU Langone Perlmutter Cancer Center
March 4th 2024

Dr Joshua Sabari Discusses Amivantamab’s First-Line Approval for NSCLC

Maggie L. Shaw
The approval converts the May 2021 accelerated FDA approval for second-line treatment of non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations to a full approval in the first line following results from the phase 3 PAPILLON study.
Lung cancer science and technology | Image credit: sergey nivens - stock.adobe.com
February 29th 2024

Robotic Lobectomy Techniques Yield Comparable Outcomes in NSCLC

Maggie L. Shaw
Investigators were searching for answers to the question, “Does it matter if a vein- or artery-first approach is used when performing a robotic lobectomy for non-small cell lung cancer (NSCLC)?
Nivolumab | Image credit: luchschenF - stock.adobe.com
February 27th 2024

Nivolumab Continues to Produce Beneficial NSCLC Outcomes

Maggie L. Shaw
This most recent analysis from the CheckMate 9LA trial provides 4-year follow-up data on patients with stage IV metastatic/recurrent non–small cell lung cancer (NSCLC) randomized to treatment with nivolumab plus ipilimumab and chemotherapy vs chemotherapy alone.
FDA logo on gray paper | Image credit: Araki Illustrations - stock.adobe.com
February 19th 2024

FDA Accepts BLA for Datopotamab Deruxtecan for Nonsquamous NSCLC

Laura Joszt, MA
The application is based on results of the phase 3 TROPION-Lung01 trial of datopotamab deruxtecan in nonsquamous non–small cell lung cancer (NSCLC), first presented at the 2023 European Society for Medical Oncology Congress.
FDA logo | Image: FDA
February 19th 2024

Osimertinib With Chemo Gains FDA Approval for EGFR-Mutated NSCLC

Mary Caffrey
Besides the new approval, AstraZeneca released preliminary results for LAURA evaluating osimertinib after chemoradiotherapy.
Tennessee Oncology’s Brandes Sees Progress in Biomarker Use in NSCLC, but “There’s Work to Be Done”
February 15th 2024

Tennessee Oncology’s Brandes Sees Progress in Biomarker Use in NSCLC, but “There’s Work to Be Done”

Mary Caffrey
Coverage of Tennessee Oncology's Johann Brandes, MD, on "Precision Medicine in NSCLC."
Abstrat image of lung cancer | Image credit: Tex Vector - stock.adobe.com
February 12th 2024

Durvalumab Consolidation Therapy Shows Promise in Elderly Patients With Stage III NSCLC

Maggie L. Shaw
Consolidation durvalumab led to comparable outcomes among older patients with unresectable stage III non–small cell lung cancer (NSCLC) vs a younger cohort with the same cancer; this patient population was underrepresented in the PACIFIC trial.
Biomarkers DNA Biology Evidence Word 3d Render Illustration | Image credit: iQoncept - Adobe Stock
February 9th 2024

In-House Biomarker Testing Shortens Time to Treatment Decision for mNSCLC

Maggie L. Shaw
This retrospective analysis compared molecular testing outcomes among newly diagnosed cases of metastatic non–small cell lung cancer (mNSCLC) from 2 periods: March 2017 to May 2019 and July 2019 to March 2021.
Dr Mark Socinski
February 7th 2024

Dr Mark Socinski on the Need for Lung Cancer Screening in Eligible Patients

Rose McNulty
Mark A. Socinski, MD, executive director at AdventHealth Cancer Institute, discusses the importance of lung cancer screening in eligible patients, including the need for primary care providers to ensure screening is being implemented.
Inflamed lungs | Image credit: SciePro - stock.adobe.com
January 30th 2024

Pneumonitis Risk in NSCLC Remains Uncertain, Obesity May Be Predictor

Maggie L. Shaw
Outcomes were evaluated among veterans treated for non–small cell lung cancer (NSCLC) from 2017 to 2020 with durvalumab, a PD-L1 inhibitor.
Dr Melinda Aldrich - Vanderbilt University Medical Center
January 25th 2024

Dr Melinda Aldrich on Disparities and the Importance of Screening in Lung Cancer

Hayden E. Klein Rose McNulty
Melinda Aldrich, PhD, MHE, associate professor in the Vanderbilt University School of Medicine in the division of genetic medicine, discussed her ongoing research aiming to identify the drivers of disparities in lung cancer outcomes in the US.
<1234>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo